SLXN is Silexion Therapeutics Corp (Healthcare) — a non-dividend-paying stock. Trading at $0.36. Market cap: $2M.
Stock snapshot
| Price | $0.36 |
| Market cap | $2M |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
About SLXN
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
Related non-dividend companies
Other non-dividend stocks investors research alongside SLXN. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is SLXN's current stock price?
SLXN (Silexion Therapeutics Corp) is currently trading at $0.36.
Does SLXN pay a dividend?
SLXN (Silexion Therapeutics Corp) does not currently pay a regular dividend.
Track SLXN in DiviDrip
Add SLXN to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search SLXN and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-08-30. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.